Over 300 Texas Auctions End Today - Bid Now
Over 30 Total Lots Up For Auction at Two Locations - WI 05/27, NV 05/29

Gordon Gunnlaugsson

SHINE Appoints new member to board of directors
June 06, 2018
Molecular Imaging PET SPECT
Gordon Gunnlaugsson
Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that Gordon (Gordy) Gunnlaugsson has been appointed to its Board of Directors. Richard (Dick) Leazer, one of the board’s longest-⁠serving members, is retiring after 8 years of service.

“Gordy is an accomplished business leader and an experienced board member,” said Gregory Piefer, founder and CEO of SHINE. “I am
confident that he will add great value to our Board of Directors and that SHINE will benefit from his insights, judgment and counsel. It is with great enthusiasm that I welcome him to the board.”

stats
DOTmed text ad

Your Trusted Source for Sony Medical Displays, Printers & More!

Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.

stats

Mr. Gunnlaugsson has been a Principal at Lakeview Equity Partners, LLC, a private equity firm in Milwaukee, WI since 2005. Prior to his role at Lakeview, he served as Executive Vice President and Chief Financial Officer from 1976 to 2000 at Marshall & Ilsley Corporation (M&I), a diversified financial services corporation that combined with Harris Bank in 2010 to create BMO Harris Bank. A Certified Public Accountant, he also holds a bachelor’s degree in business and an MBA from the University of Wisconsin.

Mr. Gunnlaugsson has previously served on the boards of Fiduciary Management, Inc., Thrivent Trust Company, West Bend Insurance Company and many others throughout his career. He has also served as a member of Wisconsin Investment Partners (a Madison-based angel group), Chairman of the Milwaukee Economic Development Corporation, Chairman of the UW School of Business Dean’s Advisory Board, and Chairman of the Advisory Board at the Cardiovascular Research Center of the Medical College of Wisconsin.

“Dick Leazer has been a leader, a mentor and a friend. We owe him a huge debt of gratitude for his service. He has been with SHINE from its inception and has helped SHINE grow from an upstart technology company to the leader in the effort to create an affordable, domestic supply of medical isotopes,” said Piefer.

Mr. Gunnlaugsson’s appointment comes as SHINE prepares for construction of its medical isotope production facility in Janesville, Wisconsin. Once operational, the SHINE facility will produce molybdenum-⁠99 (moly-⁠99) and other medical isotopes.


About Moly-⁠99
Molybdenum-⁠99 (moly-⁠99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-⁠99m). Tc-⁠99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-⁠effective and environmentally friendly technology to produce medical isotopes, including moly‑99.


About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-⁠stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for moly-⁠99. In 2014, SHINE announced the execution of moly-⁠99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE moly-⁠99 can act as a drop-⁠in replacement for reactor-⁠based moly-⁠99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-⁠99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals.

You Must Be Logged In To Post A Comment

 

advertisement

Molecular Imaging Homepage

EXPLORER scanner cuts total-body PET imaging time for cancer detection to 20 minutes
Uses a variation of the Patlak plot — called the relative Patlak plot — to generate high-quality parametric images
OEMs dominate PET/CT service landscape, IMV reports
Among midsized hospitals, OEM support stood at 77%, with 20% in-house and 13% ISO
IBA debuts compact synthesizer for radiopharmaceutical manufacturing
CASSY is designed to integrate into existing lab workflows and optimize space within hot cells
Ratio Therapeutics plans radiopharmaceutical manufacturing site in Salt Lake City
Designed for end-to-end production of radiopharmaceuticals, with an eye toward scaling up for commercial supply
SHINE Technologies to acquire Lantheus’ SPECT division
Deal includes the manufacturing operations at Lantheus’ North Billerica, Massachusetts site
Blue Earth Therapeutics begins phase 2 trial of lutetium-based radioligand for prostate cancer
Assessing efficacy and safety across different dosing regimens
SpectronRx passes FDA inspection with no observations for Indianapolis facility
Plans to expand operations to meet global demand for radiopharmaceuticals
SHINE enters UAE market with Modawina partnership for Lu-177 distribution
Extends presence across the Europe, Middle East, and Africa regions
PET procedure volumes in US rose 12% in 2024
Demand grew alongside limited expansion in installed imaging capacity, according to IMV
SHINE and Sumitomo form partnership to expand radioisotope supply in Asia
The agreement will focus on establishing supply chains for SHINE’s core offerings